Several preclinical animal models have shown its critical role in tumour immunity, as only its depletion (by anti-CD25 depleting antibody or CD4 depletion in mice) or conversion into effector T cell can contribute to anti-tumour immunity, preventing tumour growth. Here, CD4 is linked to neoplasm.